Total : %
10.18.19 02:46:50AM
Biotech Movers
Quarter 3 2019
| Winners |
|---|
| CAPR +93.48% (Positive HOPE-2 trial) |
| Losers | ||||
|---|---|---|---|---|
| No data found. | ||||
| Sell the Gap | ||||
|---|---|---|---|---|
| No data found. | ||||
| Reversal off Lows | ||||
|---|---|---|---|---|
| No data found. | ||||
Quarter 2 2019
| Winners |
|---|
| ABIO +98.64% (P2B data published in ACC) |
| ADMA +24.32% (FDA approval) |
| AGN +25.36% (buyout by ABBV) |
| DMPI +140% (-49.75% next day on offering; rallies on clinical updates in ASCO) |
| GNCA +19.61% ( +110% in 2 days rally; GEN-009 presented at ASCO) |
| LJPC +92.48% (positive P2 study of LJPC-401) |
| MBIO +112.03% (clinical data update) |
| MBRX +168.47% (FDA fast track) |
| MRTX +31.58% ( rallies on AMGN P1 Kras data) |
| PETX +39.65% (buyout) |
| PHAS +30.18% (technical momentum) |
| PRVB +217.01% (Data published in NEJM) |
| SGMO +28.96% (clinical update) |
| SOLY +42.62% (FDA 510(k) Clearance for RAP device) |
| Losers |
|---|
| ACER -78.63% (CRL from FDA) |
| ADXS -31.36% ( secondary pricing at $4) |
| AMRX -35.98% (announces restructuring plan for $50M annual savings) |
| AVEO -29.02% (slump on stock sale) |
| BCRX -52.91% (announced result from P3 Apex- 2 trial) |
| CBAY -45.45% (data not significant compared to placebo) |
| EVOK -47% (FDA CRL) |
| HRTX -18.13% (FDA CRL) |
| IFRX -91.79% (failed data) |
| IMGN -32.06% (FDA recommends new P3 trial of mirvetuximab soravtansine) |
| NBRV -27.42% (FDA CRL) |
| OCUL -22.55% (P3 OTX-TP failed to meet primary endpoint) |
| SVRA -75.21% (failed P3 Imapala study primary efficacy endpoint) |
| SYRS -23.28% (offering) |
| ZGNX -22.93% (Refusal to file letter from FDA) |
| ZSAN -26.75% (offering) |
| Sell the Gap |
|---|
| ADXS-40% (from $10.80 to $6.51) |
| TGTX -14% (from $9.30 to $8.09) |
| VKTX (-18 reversal from $11.03-$9.97) |
| Reversal off Lows | ||||
|---|---|---|---|---|
| No data found. | ||||
Quarter 1 2019
| Winners |
|---|
| ACHV +84.36% (announces final data from cytisinicline study) |
| AKTX +224.18% (Positive FDA meeting for pre-IND) |
| ALDX +35.99% (postive topline P3) |
| ARQL +67.38% (earnings update) |
| ASND +74% (positive Phase 3 data) |
| ATOS +368.21% (FDA approval of Oral Endoxifen) |
| AXSM +161.22 (Meet P2 endpoints) |
| BPTH +160.46% (rally on clinical update on P2 PREXIGEBERSEN) |
| BPTH +223.29% (low floater) |
| CELG +20.69% (acquired by BMY) |
| CMTA +74.43% (BUYOUT) |
| DERM +84.36% (positive topline 2b) |
| EOLS +26% (FDA approved wrinkle drug) |
| IMDZ +309.86% ( acquired by Merck for $5.85/ share) |
| INSM +43.23% (drug sales update Arikayce) |
| LOXO +66.33% (LLY $8 B buyout) |
| MCRB +24.85% (Collaboration) |
| MGNX +130.42% (success P3 data) |
| NITE +66.09% (Buyout from BIIB) |
| ONCE +120.09% (BUYOUT) |
| PHAS +67.47% (P1 PB2452 data) |
| SAGE +42.68% (P3 succeeds) |
| TNDM +25.20% (earnings report beat) |
| Losers |
|---|
| ACIU -65.98% (discontinue P3) |
| BIIB -29.23% (discontinue P3 ENGAGE & EMERGE ALZ trials w/ Eisai) |
| CANF -31.00% (fail data) |
| GNMX -75.32% (AEVI-001 failed) |
| IMMU -26.42% (CRL from FDA) |
| LJPC -50.19% (sales missed expectation) |
| LXRX -22.60% (Adcom split decision for Sotagliflozin approval) |
| PETX -26.55% (Engaged Capital cut it stake) |
| PRTO -85.60% (negative data) |
| PT -68% (CF data) |
| REPH -34.05% (CRL from FDA) |
| SELB -21.03% (SEL-212 update) |
| SGMO -30.87% (SB-318 no clinical benefits) |
| SLDB -67.82% (muscular dystrophy data failed) |
| TYME -35.39% (SM-88 data) |
| VNDA -19.95% (filed complaint against FDA seeking to lift clinical hold on tradipitant) |
| Sell the Gap | ||||
|---|---|---|---|---|
| No data found. | ||||
| Reversal off Lows | ||||
|---|---|---|---|---|
| No data found. | ||||
Quarter 4 2019
| Winners |
|---|
| RETA +56.99% (record high;Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia, or FA, met its primary endpoint) |
| RLMD +134.03% (record high; reports REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures) |
| Losers | ||||
|---|---|---|---|---|
| No data found. | ||||
| Sell the Gap | ||||
|---|---|---|---|---|
| No data found. | ||||
| Reversal off Lows | ||||
|---|---|---|---|---|
| No data found. | ||||
Quarter 4 2018
| Winners |
|---|
| AIMT +15.48% (rallies on DBVT withdrawal of Viaskin Peanut application) |
| ARNA +21.62% (License agreement with UTHR) |
| BHVN +25.39% (reported topline P3 trial of ZYDIS ODT) |
| CMTA +48.23% (NDA for Palovarotene) |
| CORI +53% (buyout by Gurnet Point Capital) |
| ECYT +50.39% (Buyout) |
| GBT +47.81 % (FDA accept AA) |
| NK +37.27% (announces results of haNK in novel cancer memory vaccine immunotherapy) |
| PTI +447.62% (positive preliminary from P1 study) |
| QURE +35.66% (dose confirmation AMT-061) |
| RVNC +19.47% (RT002 data and license agreement with Fosum Pharma) |
| TSRO +58.47% (buyout from GSK) |
| Losers |
|---|
| ABUS -33.99% (Update HBV development programs) |
| ADAP -30.11% (data update at ESMO) |
| ADRO -30.41% (data update) |
| ADVM -26.59% ( to discontinue lead asset ADVM -043) |
| AFMD -24.41% AFM11 (Patient death) |
| AMRN -32% (sell the news after REDUCE-IT data update) |
| CLSD -62.77% (failed phase 3) |
| DOVA -56.64%( 3 days sell off- launch of Doptelet is slower than expected & CEO changes) |
| DVBT -59.29% (withdraws Viaskin Peanut application) |
| IDRA -39.70% (ILLUMINATE-204 data) |
| IMDZ -50% (Discontinue P 3 SYNOVATE) |
| INFI -45.42% (Phase 1b data update at SITC) |
| MDXG -41.16% (delisting notification) |
| MNLO-39.57% (failed data) |
| ONCS -49.81% (preliminary KEYNOTE-695) |
| PBYI -48.01% (earnings sales disappointment) |
| SELB -33.36% (P2 SEL-212 data) |
| SGYP -69.28% (bankruptcy concerned) |
| SNNA -37.59% (SNA-120 data) |
| SPPI -38.79% (FDA did not grant BTD to Poziotinib for NSLC treatment) |
| SURF -47.50% ( reduces scope for CD47 program, accelerates SRF388IND) |
| TRVN -64.09% (FDA briefing docs) |
| Sell the Gap |
|---|
| AKBA -30% (high $10.06 to low $7.72) |
| MDGL -31% (High $190 to low $145.43, sell the news data) |
| MRNS -41% ( 5 days after the gap up) |
| PTLA -25% (High $25.00 to low $19.80) |
| VKTX -19% (high $13.78 to low $11.28. Sell the news data) |
| Reversal off Lows |
|---|
| ACRX +40% (two days reversal after FDA docs) |
Quarter 3 2018
| Winners |
|---|
| ACAD +26.56% (FDA find no safety issues in Nuplazid) |
| ACIU +38.28% ( rallies in sypathy of BIIB positive Alzheimer's news) |
| ADMP +50.00% (distribution agreement with Sandoz Inc) |
| AFMD +246.88% (collaboration news) |
| ALDX +34.85% (positive P2 dry eye data) |
| AMRN +314.72% (successful Phase 3 data) |
| ARQL +20.11% ( technical breakout) |
| ARWR +37.52% (ARO-HBV data) |
| AVXL +43.66% (initiate Phase 2b/3 clinical trial) |
| BIIB +19.63% ( rallies on positives of its Alzheimers drug data) |
| CRBP +53.62% (Expand compound focused) |
| GLMD +21.23% (Cantor $59 price target) |
| INSY +34.05% (FDA fast track Epinephrine nasal spray) |
| MNKD +89.09% (Collaboration with UTHR) |
| OBLN +52.00% (raise $10M in private placement) |
| PRQR +120.75% (Interim Phase 1/2 result) |
| PTGX +56.21% (Phase 2 Propel study) |
| REPH +26.49% (update FDA meeting IV meloxicam) |
| RETA +64.98% ( Positive results of Phase 2 bardoxolone methyl for CKD/ CARDINAL study) |
| SBBP +30.89% (Positive Phase 3) |
| TORC +49.50% (positive Phase 2 data) |
| VKTX +87.30% (succeed mid-stage study) |
| VTGN +37.50% (FDA fast track) |
| VXRT +88.85% (technical breakout) |
| ZGNX +20.30% (Phase 3 achieved endpoint) |
| Losers |
|---|
| ACOR -24.50 % (Court appeal denied for Ampytra patents) |
| AKCA -25.33% (CRL from FDA) |
| AVEO -24.21% ( TIVO P3 data readout moves to Q3) |
| BLPH -68.85% (DMC rec stopping P3) |
| CTIC -43.36% (Delayed data until 2Q 2019) |
| GEMP -52.04% (FDA asks for more data) |
| GERN -62.92% (discontinuation trial) |
| GTXI -92.27% (failed P2) |
| MDXG -38.50% (CEO, COO resigned) |
| MRSN -31.59% (clinical hold for XMT-1522 trial) |
| ONCE -27.83% (safety concerns for Hemophilia trial) |
| OVID -36.55% (Positive data, but investors questions) |
| PGNX -17.88% (P3 co endpoints met and misses) |
| SGMO -23.62% (16 week clinical SB-913 data) |
| SPPI -22.66% (Sell-off due to update Ponzi data) |
| TGTX -44.32% (DSMB cannot be conducted) |
| TSRO -23.55% (Disappointing earnings sales numbers) |
| VTL -98.85% (Failed P3 data) |
| ZYNE -24.09% (offering news) |
| Sell the Gap |
|---|
| TORC +13.4% (+28% initial spike on reports of P2a of TORC1 |
| Reversal off Lows |
|---|
| ACIU +56% (Stock move with Biogen Inc Alzheimer's disease news) |
| SNNA -4.46% (-18.66% intraday low; 2 SNA-001 trials did not meet secondary endpoints) |
Quarter 2 2018
| Winners |
|---|
| ABEO +18.21% ($16.55 closing, in lieu of AVXS buyout) |
| ALNY +29% (Movers of 12 days straight gain) |
| ALXN +14.50% (Positive Phase 3) |
| ARMO +67.00% (Buyout from LLY) |
| AVGR +72.87% (FDA clearance on PAD device) |
| AVXS +81.57% ($210.46 closing,Buyout from NVS) |
| AXON +160% (Licensing agreement for OXB-102) |
| BLCM +20.29% (Clinical hold lifted studies BPX-501) |
| BOLD +14.76% ($32.26 closing, in lieu w/ AVXS buyout) |
| CARA +42.76% (joint venture with Fresenius) |
| CLBS +67.34% (technical breakout) |
| CLLS +25.38% (Pfizer 8% stake) |
| DCPH +47.86% (Target raised to $33 at JPMorgan) |
| EDAP +62.90% (received FDA clearance for Focal One) |
| EIGR +41.77% (expands license agreement with Merck) |
| GEMP +94.47% (positive INDIGO data) |
| GLMD +151.29% (Clinical data update) |
| HRTX +30.13% (positive topline data) |
| HTBX +94.86% (Low floater technical breakout) |
| INNT +41.54% (technical breakout) |
| KPTI +10.93% (Positive Phase 2 data) |
| MDGL +144.96% (MDL-3196 achieve endpoints) |
| MNOV +18.88% (P2 trial of MN-001 interim result) |
| OMER +23.31% (Earnings report reaction) |
| ONCE +13.37% ($70.36 closing, in lieu of AVXS buyout) |
| PFNX +31.15% ('positive' top-line PF70) |
| PTCT +27.72% (interim data FIREFISH study update) |
| PTCT -30.58% (negative mover from SRPT news) |
| PTLA +25.64% (Andexxa approved by FDA) |
| RIGL +16.72% (PDUFA date unchanged to April 17) |
| SLDB +46.36% (positive move from SRPT news) |
| SLS +150.72% (positive interim data from p2b NeuVax Trial) |
| SPPI +41.90% (update MD Anderson Phase 2 data of poziotinib) |
| SRPT +36.76% (preliminary positive gene therapy for DMD) |
| STDY +77.36% (buyout) |
| VBLT +39.53% (positive data MOSPD2 plaform) |
| VKTX +101.01% (Sympathy to MDGL data) |
| VLRX +76.27% (Glooko partner for V-Go SIM) |
| VSTM +31.39% (Poster presentation at EHA) |
| XBIO +103.90% (Low float technical move) |
| XLRN +42.79% (Luspatercept positive data) |
| Losers |
|---|
| ACAD -23.36% (report of deaths and Nuplazid, CNN report) |
| AKAO -24.76% (Adcom voted against BSI) |
| AKER -33.58% (withdraw its 510k FDA Application for PIFA Chlamydia) |
| AKRX -33.76% (Fresenius terminates merger) |
| ALKS -21.96% (FDA Refusal to File letter received for ALKS 5461) |
| AMRX -17.98% (earnings reaction*$15.01 closing) |
| ANIK -24.68% (earnings reaction) |
| ANIK -37.62% (CINGAL 16-02 did not achieve its primary endpoint) |
| AQXP -84.72% (cystitis drug fail) |
| ASNS -77.19% (discontinuation of Phase 2 ASN100) |
| BMY -7.79% ( sell off on NSCLC data, $54.08 closing) |
| CBIO -63.92% (slide on update CB2679d IX program) |
| CELG -4.47% (4/30* reaction on RTF for OZANIMOD could take up to 3 years* $87.10 closing) |
| CLDX -64.60% (P2b METRIC study did not meet primary endpoints) |
| CLSD -32.19% (Underwhelming 'postive' data ) |
| CNAT -31.45% ($4.12 closing) Phase 2b trial of liver transplant patients misses primary endpoint |
| DERM -22.61% ( slump on Investor & Analyst day presentation, 5/24) |
| ESPR -35.11% (Safety concerns on data) |
| FLKS -75% (End two studies FLX-787) |
| INCY -22.93% (failed Phase 3 study ECHO-301 ) |
| JNCE -33.66% (ICONIC data update) |
| JNCE -35.20% (underwhelming abstract) |
| LPTX -23.10% (Stock selling off after clinical data at AACR) |
| MACK -43.83% (discontinue pancreatic study) |
| MNLO -76.80% (failed Phase 2) |
| NBRV -16.57% (Company said data meets all primary endpoints) |
| NERV -9.56% (earnings reaction) |
| NKTR -41.32% (Update ASCO data NKTR-214) |
| NLNK -42.62% (Company review combo study after INCY & MRK failed study) |
| PBYI -20.67% (delayed data to 2h 2018) |
| PRTA -68.78% (discontinues NEOD001) |
| PTGX -22.38% (PTG-100 data dealyed 3Q 2018) |
| PTIE -71.51% (voted 14-3 against approval) |
| REPH -54.67% ( slumped on FDA CRL for IV Meloxicam) |
| SPHS -40.27% (discontinue study due to patient death) |
| VTVT -78.08% (Failed Phase 3 data) |
| Sell the Gap |
|---|
| CALA -2.36% (+17.3% intraday high; FDA fasttrack designation for CB-839) |
| CMTA -20.88% (+1.74% intraday; +6% premarket after Ph 2B data of Palovarotene treatement for FOP) |
| DVAX -21% (Gap up +16% on abstract data to red closed -4.56%) |
| RGNX +15.62% (+31% intraday high; $31.45 closing) |
| Reversal off Lows |
|---|
| BHVN +40% (reversal off low in 13 days after clinical update) |
| NKTR -7% (-19% intraday, dropped on BMY cancer data, $93.47 closing) |
| SELB +35% (reversal with four straight green days after data sell off) |
| VTVT +128.12% (Two days reversal move +43.25% and 84.87%) |
Quarter 1 2018
| Winners |
|---|
| ADMP +31.37% (Updates Symjepi commercialization plans, including seeking a commercial partner) |
| ALDR +17.37% ( Eptimezumab met primary endpoint in PROMISE 2 trial |
| AMAG +29.14% ( FDA approval of Amag Pharmaceuticals NDA for Makena) |
| ANAB +9.29% ( in lieu of DVBT move) |
| ANTH +43.79% ( Roth initiated w/ BUY $10 target; $2.43 closing) |
| APOP +37.78% (Successful transplant using ApoGraft |
| ARNA +28.68% (positive phase 2 reults from OASIS trial) |
| ARRY (+15.54%) OS data from P3 COLUMBUS trial |
| BLUE +10.63% ( in lieu of JUNO/ CAR- T acquisitions) |
| BOLD +14.86% (-23.32% after 2 days) (*positive data of 1st dose cohort of ASPIRO Ph1/2 of AT132, record high) |
| CALA +16.55% (Citi upgrades to BUY w/ $14 price target) |
| CCXI +39.42% (secures up to $100M in new capital commmitments |
| CHRS +30.22% (Closing at $11.85 after earning update) |
| CLSD +25.36% (3/6/18* 2nd day run* $12.95 closing) |
| CLSD +32.10% (Positive CLS-TA trial) |
| CRSP +14.90% ( upgraded by SunTrust and raised price target to $45 from $16) |
| DARE (+50.00) enters into license and collaboration agreement with SST |
| DVBT +25.74% ( FDA supports submission of Viaskin Peanut application) |
| GBT +19.07% ( FDA Breakthrough Therapy Designation for Voxelotor.) |
| HRTX +26.98% (Phase 3 success data HTX-011) |
| IMGN +18.35% ( 52 weeks high/ technical breakout) |
| INFI +31.40% (closing at $2.72 technical breakout day) |
| INNT +188.33% ( 2days run; $17.30 closing) |
| MDGL +10.78% |
| NVAX +59.40% (Price target raised to $10 FROM $2.25 at B. Riley FBR |
| NVRO +14.40% ( receives FDA approval for SENZA ll SCS System) |
| OMER +35.31% (Amid favorable Medicare Policy in Congressional Spending Bill) |
| PIRS (+20.14%) entered collaboration with SGEN |
| PTI +54.11% (FDA grants breakthrough therapy) |
| PTIE +103.15% (Positive Topline for Nasal Abuse |
| RGNX +26.90% (record high post Q4 '17 earnings report; $37.50 closing* |
| RKDA +311.23% (low floater with news wheat program breakthrough) |
| SGMO +14.41% (Collaboration with CELG) |
| SRNE +17.75% ( Closing at $9.95, FDA approves ZTlido) |
| TENX +128.45% ( announced publication of a positive pre clinical study of levosimindan* $10.60 closing) |
| VKTX +14.31% ( strong price of secondary $5 at 11M shares) |
| VTVT +28.43% ( technical breakout) |
| ZSAN +24.56% (3/6/18*$9.28 closing; technical run up) |
| ZSAN +27.25% (3/8* $18.49 closing) |
| ZSAN +56.57% (3/7* $14.53 closing) |
| ZSAN +72.20% (3/5* $7.68 closing, patent announcement rally) |
| Losers |
|---|
| ABBV -12.76% ((P2 trial Rova-T disappointing data) |
| ACAD -20.04% (closing at $24.92, earning report missed) |
| ADMS (-21.85%) Approval of a competing product from Osmotica |
| AKRX -38.41% (Fresenius may back out of Akorn deal if probe finds breaches) |
| ANTH -80.87% (Phase 3 failed) |
| ARDM (-33.92%) FDA Antimicrobial Drugs Advisory Committee did not rec'd approval |
| AXON -19.63% ( CEO Dr. Hung & COO stepped down |
| AXON -56.98% ( intepirdine did not meet primary endpoint |
| AXSM -35% ( discontinued CREATE-1 trial) |
| BIIB (-6.60%) Alzheimer's uncertainty result |
| BLCM (-25.85%) Clinical hold BPX-501 |
| CDTX -24.05% (Stock selling after Phase 2 data update) |
| CELG --9.04% (closing at $87.12, refusal to file from FDA) |
| DERM -65.86% (Phase 3 trial failed to meet the co-primary endpoints) |
| EIGR (-49.38%) failed 2 LIBERTY to meet primary endpoint |
| EXAS -9.95% (sell off on ASCO abstract) |
| EYEG -41.54% ( EGP-427 P2B did not meet co- primary endpoints) |
| INSY -26.31% (+11.23% weekly gain Jan 2-5* despite 1 dy sell off*) |
| KALA -29.28% Topline result for two phase 3 trials |
| MDXG (-39.56%) postpones FY17 earning report |
| OHRP -81.33% data did not meet endpoint |
| PBYI -28.82% ( receives negative trend vote over MAA for Neratinib) |
| PTGX -57.17% (discontinue P2b PROPEL study) |
| PTLA -25.43% (3/1 FDA requires additional randomized trial for Andexxa/ $31.56 closing) |
| PTLA -6.86% ($44.91 close; receives + CHMP opinion on Andexxa, but negative on Bevyxxa) |
| SLDB -64.58% (Closing at $9.32,. IGNITE DMD trial put on clinical hold by FDA) |
| SNSS -42.39% (Delayed Next-gen BTKi due to slow enrollment) |
| TTPH (-60.41%) IGNITE3 trial did not achieve its co-primary endpoints |
| VBLT -61.03% (closing at $2.65 after failed phase 3) |
| VRX -11.41% (closing at $16.39, earning report missed) |
| Sell the Gap |
|---|
| AIMT -6.02% ( +12.90% intraday high; +25% premarket high; reported positive P3 Palisade trial in Peanut allergy) |
| ALXN +3.38% (Stock up 11% to $137.88 high from ALXN1210 data0 |
| ARGS +.69% ( +37% after hours trading; licensed PD1 checkpoint inhibitors) |
| BOLD -23.30% in 2 days ( giving up all its gain after AT132 P1/2 data release) |
| KDMN -21.28% ( KD025 data - +10.53% intraday; +15.7% after hours, $3.81 closing) |
| NVAX +4.61% (3/1* +26% intraday* reports positive flu vac* $2.27 closing) |
| RETA -.04% ( +7.64% intraday; +8.7% after hours; says patients treated w/ Bardoxolone experienced benefits on their kidneys) |
| Reversal off Lows |
|---|
| BHVN -7.27% (from -20% premarket after P3 migraine study met endpoints) |
| DBVT-3.21% (-8% intraday low, in lieu of AIMT + P3 Palisade trial) |
| GLMD +93% in 2 days ( initially dropped -62% top-line results from the ARRIVE Trial) |
| KALA +32% bounce in 5 days since initial gap down reaction on P3 result of Topline data |
Quarter 4 2017
| Winners |
|---|
| ADMS +21.01% (*Evercore ISI gives it $85 price target, plus Point72 reported 5.1% passive stake*) |
| ANAB +101% (reported positive results of P2a ANB020) |
| ARDX +44.44% (*Tepanor study meets endpoints*) |
| ARGX +78.8% (+91% weekly gain; ASH'17 data update pn Phase 1/2 clinical trials for AML & CTCL ARGX-110) |
| BIOC +69.12% (* announces issuance of U.S patent core to BIOC Target Select Assays for ctDNA) |
| BLUE +17.91% (*ASH '17 data presentation of its Lentiglobin; record high $10bil MC) |
| CBIO +29.62% (announces acceleration of Phase 1/2 trial of CB 2679d/lSU304 in individuals w/ Hemophilia B) |
| CLSN +123.33% (*weekly gain, rallies on aanouncement of final clinical & translational research data from its OVATION Study*) |
| ECYT +307.8% (*weekly gain on completion of an exclusive worldwide license of PSMA-617 from ABZ GmbH*) |
| FLXN +23.78% (*weekly gain, FDA approved its Zilretta drug*) |
| INFI +123.35% (Wells Fargo Upgrade to $5PT,cites IPI-549 potential*) |
| MDGL +88.29% (met primary endpoint in a P2 NASH study for MGL-3196*) |
| MNKD +131.80% (*weekly gain, on FDA update on Affreza prescribing information*) |
| MRNS +39.58% (*sympathy move with MDGL*) |
| ONCS +60.00% updated data from P2 OMS I-102 . |
| OTIC +83.04% reporting 'positive' Phase 3 Otividex trial |
| PTI +161.28% (*positive data from PTI-428,PTI-801,& PTI-808*) |
| RVNC +33.65% (RT002 met primary and secondary endpoints) |
| SAGE +54.25% (positive trial results in postpartum depression) |
| VKTX +35.10% weekly gain (* sell the gap initial reaction, next 2 days +45% bounce, rally in sympathy move w/ MDGL*) |
| VTVT +44.82% weekly gain (rallies on increase stake of Ron Perelman) |
| Losers |
|---|
| ACOR -39.72% (tozadenant for Parkinson's groups, five of which were fatal) |
| ACRX -59.81% (*receives CRL from FDA for DSUVIA*) |
| CALA -41% in two days. (CB-839 combo fail to impress investors at SITC) |
| FPRX -40.90% (*tanked on Cabiralizumab abstract presented on SITC*) |
| GALT -30.65% (P2b NASH-CX trial update) |
| GBT -14.24% (ASH '17 presented treatment for SCD #Voxelotor drug. |
| JUNO -14.33% ~ initial reaction, -23.82% for the week* (ASH '17 reported additional data from TRANSCEND study) |
| JUNO -14.34% (*ASH '17 presented addtl data from TRANSCEND study of JCAR017*) |
| ONCE -34.97% (*ASH '17 presented SPK-8011; -50% intraday low; 52weeks low print*) |
| RARX -37.32% (* Met Primary Endpoint for Phase 2 RA101495, sold off on efficacy inferior to ALXN1210* |
| RDHL -29.60% offering of 4,090,909 American Depositary Shares, public offering price of $5.50 per ADS for gross proceeds to $22.5m |
| SYRS -31.69% (*ASH '17 presented new preclinical data on SY-1365; intraday low -49%) |
| Sell the Gap |
|---|
| AIMT +28.37% from +56% or 39.90 premarket high*; DVBT PH3 failure in peanut allergy is AIMT gain* |
| VKTX +9.12% (*+39% intraday, +52% premarket, sympathymove with MDGL on positive P2 data of MGL-3196*; after 2 days total rally +45%*) |
| VSTM -16.86% (+57% premarket; +10.6% intraday; ASH '17 released PH3 result of DUO*) |
| Reversal off Lows |
|---|
| BHVN -4.86% (*-28.70% intraday low, TRIGRILUZOLE Phase2/3 no difference from Placebo |
| GALT unchanged* weekly performance (*initial reaction is -32% 2 days rally brought it back to unchanged for the week*) |
| NKTR +5.71% (-5% premarket low, INHALE Ph3 study did not meet endpoint) |
Quarter 3 2017
| Winners |
|---|
| AKTX +51.20% (*Plans to advance COVERSIN towards PH3) |
| ALNY +49.32% (meets all endpoint for APOLLO Phase3 of PATISIRAN*) |
| CLSN +123.33% (*weekly gain, rallies on aanouncement of final clinical & translational research data from its OVATION Study*) |
| ZGNX +172.23% (*Meets endpoint ZX008 of Phase 3 trial for Dravet syndome*) |
| ZYNE +34.19% *ZYN002 gel meets primary endpoint in Phase 2 Fragile X syndrome trial.* |
| Losers |
|---|
| AXON -72.47% (*Failed Phase 3 MINDSET study*) |
| GNCA -72.40% (*Ceased GEN 003 and shifted focus towards Immunocology*) |
| ICPT -35.09% (FDA safety announcement on OCALIVA*) |
| VSAR -85.42% (*Phase 3 of SOMAVARATAN did not meet primary endpoint*) |
| Sell the Gap |
|---|
| NBRV +29.30% from +105% intraday high* (rallies on LEAP 1 trial) |
| Reversal off Lows |
|---|
| PTCT +8.05% (*-23% intraday low to positive territory*) |
